COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations
Brain
.
2021 Mar 3;144(2):357-360.
doi: 10.1093/brain/awaa444.
Authors
Michael P Lunn
1
2
,
David R Cornblath
3
,
Bart C Jacobs
4
5
,
Luis Querol
6
,
Peter A van Doorn
4
,
Richard A Hughes
1
,
Hugh J Willison
7
Affiliations
1
1 Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.
2
2 Department of Neuromuscular Disease, Institute of Neurology, University College London, WC1N 3BG, UK.
3
3 Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
4
4 Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.
5
5 Department of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
6
6 Department of Neurology, Hospital de la Santa Creu I Santa Pau, 8025, Barcelona, Spain.
7
7 College of Medicine, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
PMID:
33313690
PMCID:
PMC7799242
DOI:
10.1093/brain/awaa444
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
COVID-19 Vaccines
COVID-19*
Guillain-Barre Syndrome*
Humans
SARS-CoV-2
Substances
COVID-19 Vaccines